Quick Answer
Quince Therapeutics, Inc. reported Operating Income of -$57.28 million for fiscal year 2024.
Quince Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$57.28M | -65.5% |
| 2023 | -$34.62M | +33.4% |
| 2022 | -$52.02M | +42.4% |
| 2021 | -$90.32M | -14.5% |
| 2020 | -$78.89M | -101.4% |
| 2019 | -$39.17M | -223.2% |
| 2018 | -$12.12M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$13.43M | -129.1% | -28.8% |
| June 30, 2025 | -$10.43M | +63.0% | +29.8% |
| March 31, 2025 | -$14.86M | -32.4% | -153.4% |
| September 30, 2024 | -$5.86M | +3.8% | +79.2% |
| June 30, 2024 | -$28.19M | -404.9% | -151.3% |
| March 31, 2024 | -$11.22M | +13.4% | -84.1% |
| September 30, 2023 | -$6.09M | +20.0% | -9.1% |
| June 30, 2023 | -$5.58M | +65.7% | +56.9% |
- Quince Therapeutics, Inc. showed a decrease of -65.5% in Operating Income compared to the prior fiscal year.
- Over the 2018–2024 period, Quince Therapeutics, Inc.’s operating income has declined by 372.7% (from -$12.12 million to -$57.28 million).
- The most recent figure is from Quince Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: